Yu Mingjia graduated from Beijing Institute of Technology. He is mainly engaged in the research of innovative drugs, and has long been committed to the study of the structure-activity relationship between small molecules and biological macromolecular compounds. By using computer aided drug design method, drug design based on the three-dimensional structure of drug and receptor was studied, and a variety of compounds promising to be developed into new drugs were discovered. These innovative research efforts promote interdisciplinary research in organic chemistry, life sciences, and computer science.

(1) Design and development of medical polysaccharide lead compounds;
(2) Development of lead drugs for functional small molecule polypeptides;
(3) Discovery of therapeutic targets for pathogens and coronavirus-infected diseases;
(4) Design and development of new antibacterial targeted drugs.

2015.9-2019.6 School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Chemistry Major, Doctor of Science
2012.9-2015.6 Co-trained by Harbin Medical University and Wuhan University, majoring in Pharmacy, Master of Science
2007.9-2012.6 Harbin Medical University, Bachelor of Science in Clinical Pharmacy

2021.9-present, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Special Associate Researcher, Master Supervisor
2019.6-2021.8 Advanced Innovation Center for Soft Matter Science and Engineering of Beijing University of Chemical Technology and Uppsala University jointly train postdoctoral Fellows

Host project:
1.2019.12-2022.11, Participated in the Key research and development Plan of Renewable Energy and Hydrogen Energy of the Ministry of Science and Technology as the backbone of the project, 2019YFB150059, the key technology of biomass continuous preparation of high-quality biodiesel
2.2020.9-2021.6, presided over the "67th Batch of surface Funding Fund" of Chinese postdoc, 2020M670109, Rational design of Heparan sulfate drugs for the treatment of novel coronavirus infection
3.2020.10-2022.6, hosted the Second Batch of Special Grants for Chinese postdoctoral Fellows, 2020TQ0029, Design of Heparan sulfate antiviral drugs based on the domain of coronavirus spike protein receptor binding
4.2021.12-2025.5, Participated in the National Quality Infrastructure System Key Research and Development Program of the Ministry of Science and Technology, SQ2021YFF0600005, Research on the key measurement technology of emerging biological functional substance structure
5.2021.9-2024.9, presided over the Academic Start-up Program for Young Teachers of Beijing Institute of Technology, 3100012222222, Discovery and Molecular Mechanism of Heparan sulfate anti-coronavirus Lead Compounds
6.2023.1-2025.12, Chair of Young Science Foundation of National Natural Science Foundation of China, 32201053, Discovery and Molecular Mechanism of Heparan sulfate anti-Coronavirus Lead Compounds
7.2022.10-2024.10, presided over the special engineering project of the Science and Technology Commission of the Military Commission, the most advanced biological manufacturing technology
8.2023.1-2025.12, Participated in the National Natural Science Foundation of China, 52271254, Construction of Composite metal MEMS and its application in real-time monitoring of tumor organoids growth and in situ gene expression regulation
9.2023.1-2023.12, Participated in the Science and Technology Innovation Plan-Science and Technology Support Program of Beijing Institute of Technology, 3100012212314, Discovery of Heparan sulfate anti-coronavirus lead compounds
10.2023.11-2026.12, Participated in the Key Research Project of Beijing Natural Science Foundation-Haidian Original Innovation Joint Fund, L232017, Screening and evaluation of potential treatment drugs for multiple sclerosis based on Mendelian Randomized Analysis
11.2024.1-2024.12, Participated in the Key research and Development Project of Sichuan Province, 24SYSX0230, Research and development of new antibacterial drugs with double action mode driven by AI
Publication status:
[1]Zi-Qiang Feng, Jing Ding, Min-Zhen Zhu, Wei-Song Xie, Rui-Chen Liu, Si-Si Liu, Si-Meng Liu, Ming-Jia Yu*, Xin-Hong Zhu*, Jian-Hua Liang*. Discovery of a novel lead characterized by a stilbene-extended scaffold against sepsis as soluble Epoxide hydrolase inhibitors. Eur. J. Med. Chem., 2024, https://doi.org/10.1016/j.ejmech.2023.116113. < br > [2]Kiran Shehzadi, Afsheen Saba, Mingjia Yu*, Jianhua Liang*. Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2. Top. Curr. Chem., 2023, 381(5):22.
[3]Tianji Zhang#, Mingjia Yu#, Honglian Li, Marco Maccarana, Wei Zhang, Deling Shi, Ying Kan, Xiao Zhang, Lianli Chi, Tianwei Tan*. Interacting polymer-modification enzymes in heparan sulfate biosynthesis. Carbohydr. Polym., 2023, 299: 120191.
[4]Kiran Shehzadi, Mingjia Yu* and Jianhua Liang*. De Novo Potent Peptide Nucleic Acid Antisense Oligomer Inhibitors Targeting SARS-CoV-2 RNA-Dependent RNA Polymerase via Structure-Guided Drug Design. Int. J. Mol. Sci., 2023, 24(24), 17473.
and Mingjia Yu*. Identification of a Pentasaccharide Lead Compound with High Affinity to the SARS-CoV-2 Spike Protein via In Silico Screening. Int. J. Mol. Sci., 2023, 24, 16115.
[6]Xiaotian Lian, Wentian Liu, Bingzhi Fan, Mingjia Yu*, and Jianhua Liang*. Design, Synthesis and Biological Evaluation of Conjugates of 3-O-Descladinose-azithromycin and Nucleobases against rRNA A2058G- or A2059G-Mutated Strains. Molecules, 2023, 28, 3: 1327.
[7]Mingjia Yu, Huimin Zhao, Yuhui Miao, Shi-Zhong Luo, Song Xue*. Virtual evolution of HVEM segment for checkpoint inhibitor discovery. Int. J. Mol. Sci., 2021, 21; 22(12):6638.
Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins—An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic. Front. Mol. Biosci., 2021, 7:628551.
Ming-jia Yu*. Identification of Potential Antiviral Disaccharide Leading Compounds against SARS-CoV-2 through A Computer Aided Study ChemBioChem, 2022, https://doi.org/10.1002/cbic.202200461. < br > Yingxia Tan*. Elucidating the Binding Mode between Heparin and Inflammatory Cytokines by Molecular Modeling. Chemistryopen, 2021, 10(10):966-975.
[11]Ying Han, Yifan Da, Mingjia Yu, Yaping Cheng, Xin Wang, Jiale Xiong, Guoying Guo, Yan Li, Xianxing Jiang, Xiaoqing Cai*, Protein labeling approach to improve lysosomal targeting and efficacy of antibody-drug conjugates. Org. Biomol. Chem., 2020, 18(17):3229-3233.
[12]Ming-jia Yu, Shi-Lu Chen*. From Alkane to Alkene: The Inert Aliphatic C−H Bond Activation Presented by Binuclear Iron Stearoyl-CoA Desaturase with a Long di-Fe Distance of 6 A. ACS Catal., 2019, 9: 4345-4359.
[13]Ming-jia Yu, Shi-Lu Chen*. Mechanism and inhibitor exploration for binuclear Mg ketol-acid reductoisomerase: targeting on the biosynthetic pathway of branched-chain amino acids. ChemBioChem, 2019, 21(3): 381-391.
[14]Wenya Tian, Chenghai Sun, Mei Zheng, Jeffrey Harmer, Mingjia Yu, Yanan Zhang, Haidong Peng, Dongqing Zhu, Zixin Deng, Shi-Lu Chen, Mehdi Mobli, Xinying Jia, and Xudong Qu*, Efficient Biosynthesis of Heterodimeric C3-Aryl Pyrroloindoline Alkaloids. Nat. Commun., 2018, 9: 4428(1-9).
[15]Ming-jia Yu and Shi-Lu Chen*, From NAD+ to Ni Pincer Complex: A Significant Cofactor Evolution Presented by Lactate Racemase. Chem. — Eur. J., 2017, 23(31): 7545-7557.
[16] The smiles algorithm was used to generate the structural coordinates of heparin analogues randomly in batches, Yu Mingjia. Guo Xiaoliang; Lin Huang; [17]Liu Xingzhou, Yu Mingjia*, Liang Jianhua*. Research Progress on the Synthesis of Protoberberine Skeleton and its Anti-inflammatory Activity[J]. Chinese Journal of Organic Chemistry, 2023, doi: 10.6023/cjoc202209037.